BMS-103
BMS-103 is a PDL1 inhibitor (IC50 = 79.1 nM) (kd = 44 nM) . BMS-103 reduces the survival rate of acute T-lymphoblastic leukemia cells and ovarian cells. BMS-103 can be used in research on acute T-lymphoblastic leukemia and cancers such as ovarian cancer[1].
Product Specifications
CAS Number
1675202-86-4
UNSPSC
12352005
Target
PD-1/PD-L1
Related Pathways
Immunology/Inflammation
Field of Research
Cancer
Smiles
CC1=C(COC2=CC(OC)=C(CNCCO)C(OC)=C2)C=CC=C1C3=CC=CC=C3
Molecular Formula
C25H29NO4
Molecular Weight
407.50
References & Citations
[1]anesan A, et al. Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. Sci Rep. 2019 Aug 27;9 (1) :12392. d
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS616400-01 0.05 mg
Aryl Hydrocarbon Receptor Nuclear Translocator-like 2 (ARNTL2, Transcription Factor BMAL2)
Sign In for Pricing
View Details MBS616400-02 5x 0.05 mg
Aryl Hydrocarbon Receptor Nuclear Translocator-like 2 (ARNTL2, Transcription Factor BMAL2)
Sign In for Pricing
View Details 
EK346017 96 Well
Rabbit BMPR2 (Bone Morphogenetic Protein Receptor 2) ValidElisa Kit
Sign In for Pricing
View Details